JP7754723B2 - 分離部分及びその使用方法 - Google Patents
分離部分及びその使用方法Info
- Publication number
- JP7754723B2 JP7754723B2 JP2021568018A JP2021568018A JP7754723B2 JP 7754723 B2 JP7754723 B2 JP 7754723B2 JP 2021568018 A JP2021568018 A JP 2021568018A JP 2021568018 A JP2021568018 A JP 2021568018A JP 7754723 B2 JP7754723 B2 JP 7754723B2
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- moiety
- protease
- cytokine
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22015—Cathepsin L (3.4.22.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024199622A JP7863602B2 (ja) | 2019-05-14 | 2024-11-15 | 分離部分及びその使用方法 |
| JP2025089952A JP2025122188A (ja) | 2019-05-14 | 2025-05-29 | 分離部分及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847914P | 2019-05-14 | 2019-05-14 | |
| US62/847,914 | 2019-05-14 | ||
| US201962938786P | 2019-11-21 | 2019-11-21 | |
| US62/938,786 | 2019-11-21 | ||
| PCT/US2020/032988 WO2020232305A1 (en) | 2019-05-14 | 2020-05-14 | Separation moieties and methods and use thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199622A Division JP7863602B2 (ja) | 2019-05-14 | 2024-11-15 | 分離部分及びその使用方法 |
| JP2025089952A Division JP2025122188A (ja) | 2019-05-14 | 2025-05-29 | 分離部分及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532217A JP2022532217A (ja) | 2022-07-13 |
| JP2022532217A5 JP2022532217A5 (cg-RX-API-DMAC7.html) | 2023-05-23 |
| JP7754723B2 true JP7754723B2 (ja) | 2025-10-15 |
Family
ID=73289342
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568018A Active JP7754723B2 (ja) | 2019-05-14 | 2020-05-14 | 分離部分及びその使用方法 |
| JP2024199622A Active JP7863602B2 (ja) | 2019-05-14 | 2024-11-15 | 分離部分及びその使用方法 |
| JP2025089952A Pending JP2025122188A (ja) | 2019-05-14 | 2025-05-29 | 分離部分及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199622A Active JP7863602B2 (ja) | 2019-05-14 | 2024-11-15 | 分離部分及びその使用方法 |
| JP2025089952A Pending JP2025122188A (ja) | 2019-05-14 | 2025-05-29 | 分離部分及びその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210115102A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3969035A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7754723B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220023988A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114450022A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020275877B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021022666A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3137512A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL287977A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021013766A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202112541RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020232305A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7795181B2 (ja) | 2017-09-06 | 2026-01-07 | イェール ユニバーシティー | インターロイキン-18バリアントとその利用法 |
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| EP3930687A4 (en) | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| CN110862459A (zh) * | 2019-11-18 | 2020-03-06 | 温州医科大学 | Hpv16e7亲和体负载颗粒酶b的亲和毒素靶向分子及其用途 |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2022090203A1 (en) | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| KR20230096047A (ko) | 2020-10-26 | 2023-06-29 | 싸이튠 파마 | 비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제 |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| JP2024500189A (ja) | 2020-12-21 | 2024-01-04 | アロジーン セラピューティクス,インコーポレイテッド | プロテアーゼ活性化cd45ゲートcar |
| MX2023008809A (es) | 2021-01-29 | 2023-08-04 | Allogene Therapeutics Inc | ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS. |
| KR20230157448A (ko) | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| JP2024527546A (ja) * | 2021-06-30 | 2024-07-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グランザイム活性化可能な膜相互作用ペプチド及び使用方法 |
| CN118974078A (zh) * | 2022-02-04 | 2024-11-15 | 小利兰·斯坦福大学董事会 | 替代细胞因子多肽 |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
| EP4360658A1 (en) * | 2022-10-28 | 2024-05-01 | Julius-Maximilians-Universität Würzburg | Compounds for detection of oral inflammation |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| WO2024150174A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| WO2024211877A2 (en) * | 2023-04-06 | 2024-10-10 | Werewolf Therapeutics, Inc. | Il-12 prodrugs, methods of use and pharmaceutical compositions |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025072450A1 (en) | 2023-09-26 | 2025-04-03 | Werewolf Therapeutics, Inc. | Enhanced adoptive cell therapy |
| KR20260105764A (ko) | 2023-10-30 | 2026-07-07 | 알로젠 테라퓨틱스 인코포레이티드 | 조작된 세포 |
| KR20260114559A (ko) * | 2023-12-08 | 2026-07-22 | 아뮤닉스 파마슈티컬스, 인크. | 프로테아제 활성화가능 사이토카인 및 이의 제조 및 사용 방법 |
| WO2025151274A1 (en) | 2024-01-08 | 2025-07-17 | Adimab, Llc | Inducible il-18 prodrugs |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| WO2025240781A2 (en) | 2024-05-15 | 2025-11-20 | Werewolf Therapeutics, Inc. | Modified antibodies and immunoglobulin formats |
| WO2026050749A1 (en) * | 2024-08-30 | 2026-03-05 | Yeda Research And Development Co. Ltd. | Compositions and methods comprising fusion polypeptides for use in treating cancer |
| WO2026072455A1 (en) | 2024-09-26 | 2026-04-02 | Werewolf Therapeutics, Inc. | Single domain human serum albumin antibodies |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| WO2026112598A1 (en) * | 2024-11-25 | 2026-05-28 | Modernatx, Inc. | Messenger rna encoding masked proteins and compositions and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016538240A (ja) | 2013-09-25 | 2016-12-08 | シトムクス セラピューティクス,インコーポレイティド | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
| WO2019051122A2 (en) | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS |
Family Cites Families (183)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| EP0547163B1 (en) | 1990-08-29 | 2002-02-06 | Centre Hospitalier Regional De Nantes | Protein polyligands joined to a stable protein core |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| AU2660397A (en) | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| DE19701141C1 (de) | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| EP1214340B1 (en) * | 1999-09-24 | 2004-11-24 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| IT1306736B1 (it) | 1999-10-29 | 2001-10-02 | Benito Salmi | Dispositivo di contenimento e distribuzione di palloni per tiri alvolo. |
| AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20040014652A1 (en) | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| DE10045592A1 (de) | 2000-09-15 | 2002-03-28 | Klaus Pfizenmaier | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| GB0100551D0 (en) | 2001-01-09 | 2001-02-21 | Queen Mary & Westfield College | Protein |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| CA2456470A1 (en) | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| CA2841097A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| AU2003237532B2 (en) * | 2002-06-12 | 2009-07-30 | Symphony Evolution, Inc. | Human ADAM-10 inhibitors |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| KR20050049545A (ko) | 2002-10-14 | 2005-05-25 | 에프. 호프만-라 로슈 아게 | 길항제 il-15 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| RS20050501A (sr) | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polimerni konjugati citokina,hemokina,faktora rasta, polipeptidnih hormona i njihovih antagonista sa očuvanom aktivnošću vezivanja receptora |
| WO2004090135A2 (en) | 2003-04-09 | 2004-10-21 | Asterion Limited | Cytokine polypeptides and antibodies containing a signal sequence for the attachement of glycosylphosphatidylinositol |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| CN102816241B (zh) | 2004-02-09 | 2015-07-22 | 人类基因科学公司 | 清蛋白融合蛋白 |
| AU2004101073B4 (en) | 2004-12-21 | 2005-08-18 | Kerry William O'Hanlon | A Beverage Container Holder |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| WO2006110728A2 (en) | 2005-04-12 | 2006-10-19 | The Uab Research Foundation | Immunogenic cmv tegument aggregates |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| EP2474318A1 (en) | 2006-06-07 | 2012-07-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1867660A1 (en) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| WO2008021543A2 (en) * | 2006-08-17 | 2008-02-21 | Monsanto Technology, Llc | Transgenic plants with enhanced agronomic traits |
| WO2008033413A2 (en) | 2006-09-14 | 2008-03-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2008147530A1 (en) | 2007-05-24 | 2008-12-04 | The Regents Of The University Of California | Integrated fluidics devices with magnetic sorting |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| EP2288386A1 (en) | 2008-02-19 | 2011-03-02 | Asterion Limited | Modified linkers |
| WO2010014258A2 (en) | 2008-08-01 | 2010-02-04 | Nektar Therapeutics Al, Corporation | Conjugates having a releasable linkage |
| GB0815216D0 (en) | 2008-08-21 | 2008-09-24 | Asterion Ltd | Interleukin |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| US20120269765A1 (en) | 2009-07-24 | 2012-10-25 | Garcia K Christopher | Cytokine compositions and methods of use thereof |
| WO2011044563A2 (en) | 2009-10-10 | 2011-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Il-17 family cytokine compositions and uses |
| US8734774B2 (en) * | 2010-04-02 | 2014-05-27 | University Of Rochester | Protease activated cytokines |
| KR20130070576A (ko) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
| US20160354472A1 (en) | 2010-10-22 | 2016-12-08 | Protox Therapeutics Corp. | Use of human serum albumin to decrease antigenicity of therapeutic proteins |
| WO2012059486A1 (en) | 2010-11-01 | 2012-05-10 | Novozymes Biopharma Dk A/S | Albumin variants |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| WO2012106615A1 (en) * | 2011-02-03 | 2012-08-09 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| PE20150605A1 (es) | 2012-04-27 | 2015-05-28 | Cytomx Therapeutics Inc | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico |
| WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
| SG11201408554QA (en) | 2012-06-22 | 2015-02-27 | Cytomx Therapeutics Inc | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| IN2015KN00329A (cg-RX-API-DMAC7.html) | 2012-08-09 | 2015-07-10 | Univ Leland Stanford Junior | |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| WO2014100014A1 (en) | 2012-12-17 | 2014-06-26 | The Board Of Trustees Of The Leland Stanford Junior University | Super-2 complexes with antibody to augment il-2 therapy |
| JP6605957B2 (ja) | 2013-01-04 | 2019-11-13 | シトムクス セラピューティクス,インコーポレイティド | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
| US9255155B2 (en) | 2013-01-31 | 2016-02-09 | The Regents Of The University Of California | Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer |
| US20160152686A1 (en) | 2013-03-13 | 2016-06-02 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto |
| BR112015030514A2 (pt) | 2013-06-04 | 2017-08-29 | Cytomx Therapeutics Inc | Composições e métodos para conjugação de anticorpos ativáveis |
| JP6693872B2 (ja) | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス,インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| WO2015089283A1 (en) | 2013-12-11 | 2015-06-18 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| PT3134123T (pt) | 2014-02-21 | 2021-03-22 | Nektar Therapeutics India Pvt Ltd | Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1 |
| JP6592505B2 (ja) | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| BR112017023872A2 (pt) | 2015-05-04 | 2018-07-24 | Cytomx Therapeutics Inc | anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos |
| AU2016258988A1 (en) | 2015-05-04 | 2017-12-07 | Cytomx Therapeutics, Inc | Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Cytomx生物製藥公司 | 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法 |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| US20160362469A1 (en) | 2015-06-12 | 2016-12-15 | Tianxin Wang | Methods for protein modification in pharmaceutical applications |
| CN107709356A (zh) * | 2015-06-26 | 2018-02-16 | 南加利福尼亚大学 | 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| AU2017229687A1 (en) | 2016-03-08 | 2018-09-20 | Takeda Pharmaceutical Company Limited | Inducible binding proteins and methods of use |
| KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| WO2018071777A1 (en) | 2016-10-14 | 2018-04-19 | Harpoon Therapeutics, Inc. | Innate immune cell trispecific binding proteins and methods of use |
| MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| CN110072890B (zh) | 2016-11-03 | 2022-11-29 | 百时美施贵宝公司 | 可活化的抗ctla-4抗体及其用途 |
| WO2018136725A1 (en) | 2017-01-19 | 2018-07-26 | Harpoon Therapeutics, Inc. | Innate immune cell inducible binding proteins and methods of use |
| WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| US11318164B2 (en) | 2017-03-01 | 2022-05-03 | Nektar Therapeutics | Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy |
| JP2020511130A (ja) | 2017-03-09 | 2020-04-16 | サイトメックス セラピューティクス インコーポレイテッド | Cd147抗体、活性化可能cd147抗体、ならびにその作製および使用の方法 |
| EP3628010A4 (en) | 2017-05-02 | 2021-02-17 | Nektar Therapeutics | IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE |
| US20200115461A1 (en) * | 2017-05-03 | 2020-04-16 | Harpoon Therapeutics, Inc. | Compositions and methods for adoptive cell therapies |
| KR20250057110A (ko) | 2017-05-15 | 2025-04-28 | 넥타르 테라퓨틱스 | 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| JP2020528878A (ja) | 2017-06-20 | 2020-10-01 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | がん治療用インターフェロンプロドラッグ |
| US11220544B2 (en) | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
| JP2020530554A (ja) | 2017-07-20 | 2020-10-22 | シートムエックス セラピューティクス,インコーポレイテッド | 活性化抗体の特性を定性的および/または定量的に分析する方法およびその使用 |
| US12030940B2 (en) | 2017-08-17 | 2024-07-09 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
| CN111212853A (zh) | 2017-08-30 | 2020-05-29 | 西托姆克斯治疗公司 | 可活化的抗cd166抗体及其使用方法 |
| CN111356700A (zh) * | 2017-09-08 | 2020-06-30 | 马弗里克治疗公司 | 受约束的条件性活化的结合蛋白 |
| CN111247171A (zh) | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| WO2019094396A1 (en) | 2017-11-07 | 2019-05-16 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| CA3115461A1 (en) | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| CU24554B1 (es) | 2018-05-07 | 2021-11-04 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
| MX2020012251A (es) * | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| MX2020014290A (es) | 2018-06-22 | 2021-08-05 | Cugene Inc | Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos. |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| EP4004026A4 (en) | 2019-07-25 | 2023-11-15 | Trutino Biosciences Inc. | IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER |
| EP4013775A1 (en) | 2019-08-12 | 2022-06-22 | Askgene Pharma, Inc. | Il-2 fusion proteins that preferentially bind il-2ralpha |
| BR112022009110A2 (pt) * | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| PH12022552630A1 (en) | 2020-04-01 | 2023-01-04 | Xilio Dev Inc | Masked il-15 cytokines and their cleavage products |
| BR112022019708A2 (pt) | 2020-04-01 | 2022-12-20 | Xilio Dev Inc | Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer |
| PH12022552627A1 (en) | 2020-04-01 | 2023-01-04 | Xilio Dev Inc | Masked il-2 cytokines and their cleavage products |
-
2020
- 2020-05-14 BR BR112021022666A patent/BR112021022666A2/pt unknown
- 2020-05-14 CA CA3137512A patent/CA3137512A1/en active Pending
- 2020-05-14 MX MX2021013766A patent/MX2021013766A/es unknown
- 2020-05-14 WO PCT/US2020/032988 patent/WO2020232305A1/en not_active Ceased
- 2020-05-14 JP JP2021568018A patent/JP7754723B2/ja active Active
- 2020-05-14 CN CN202080050736.3A patent/CN114450022A/zh active Pending
- 2020-05-14 EP EP20804817.3A patent/EP3969035A4/en active Pending
- 2020-05-14 SG SG11202112541RA patent/SG11202112541RA/en unknown
- 2020-05-14 AU AU2020275877A patent/AU2020275877B2/en active Active
- 2020-05-14 KR KR1020217040418A patent/KR20220023988A/ko not_active Ceased
- 2020-10-28 US US17/082,955 patent/US20210115102A1/en active Pending
-
2021
- 2021-11-10 IL IL287977A patent/IL287977A/en unknown
-
2022
- 2022-02-22 US US17/677,473 patent/US11739132B2/en active Active
-
2023
- 2023-05-11 US US18/315,927 patent/US20230272028A1/en active Pending
-
2024
- 2024-11-15 JP JP2024199622A patent/JP7863602B2/ja active Active
-
2025
- 2025-05-29 JP JP2025089952A patent/JP2025122188A/ja active Pending
- 2025-08-13 AU AU2025217298A patent/AU2025217298A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016538240A (ja) | 2013-09-25 | 2016-12-08 | シトムクス セラピューティクス,インコーポレイティド | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
| WO2019051122A2 (en) | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS |
Non-Patent Citations (2)
| Title |
|---|
| Accession No. JN559769,Database GenBank [online],2012年05月16日,[令和7年7月30日検索], インターネット<URL:https://www.ncbi.nlm.nih.gov/nuccore/JN559769> |
| J.Puskas, et al.,Immunology,2011年,Vol.133, No.2,p.206-220 |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202112541RA (en) | 2021-12-30 |
| CA3137512A1 (en) | 2020-11-19 |
| JP2025020424A (ja) | 2025-02-12 |
| IL287977A (en) | 2022-01-01 |
| JP7863602B2 (ja) | 2026-05-21 |
| EP3969035A1 (en) | 2022-03-23 |
| JP2025122188A (ja) | 2025-08-20 |
| AU2020275877A1 (en) | 2021-12-23 |
| US20230272028A1 (en) | 2023-08-31 |
| AU2025217298A1 (en) | 2025-09-04 |
| US20220220181A1 (en) | 2022-07-14 |
| BR112021022666A2 (pt) | 2022-03-29 |
| US11739132B2 (en) | 2023-08-29 |
| KR20220023988A (ko) | 2022-03-03 |
| US20210115102A1 (en) | 2021-04-22 |
| CN114450022A (zh) | 2022-05-06 |
| MX2021013766A (es) | 2022-02-21 |
| AU2020275877B2 (en) | 2025-07-24 |
| JP2022532217A (ja) | 2022-07-13 |
| WO2020232305A1 (en) | 2020-11-19 |
| EP3969035A4 (en) | 2023-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7863602B2 (ja) | 分離部分及びその使用方法 | |
| JP7846073B2 (ja) | 活性化可能なインターロイキン-2ポリペプチド及びその使用方法 | |
| US12076371B2 (en) | Activatable cytokine polypeptides and methods of use thereof | |
| US20210130430A1 (en) | Activatable cytokine polypeptides and methods of use thereof | |
| CN112654635A (zh) | 可活化细胞因子多肽及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230512 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230512 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240517 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240816 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241115 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250529 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250903 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250912 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250929 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251002 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7754723 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |